Coreline Soft said Tuesday that it has obtained medical device manufacturing certification (pre-marketing approval) for its AI solution “AVIEW CHEST.”

AVIEW CHEST is AI-based medical image detection and diagnosis assistant software. It can detect abnormal findings, such as lung nodules and masses, by automating CT image analysis and capturing deep learning-based network structures to automate segmentation, measurement, and analysis of anatomical structures as well as pathology, and includes an automatic segmentation function for the aorta, according to Coreline Soft.

AVIEW CHEST is licensed as a “combination medical device.” A combination medical device combines two or more medical devices into a single device that performs multiple functions. The name of a combination medical device is listed as the medical device that performs the main function.

Included in AVIEW CHEST are Coreline Soft's licensed products: LCS, an automatic analysis solution for lung nodules; COPD, an automatic analysis solution for chronic obstructive pulmonary disease; CAC, an automatic diagnosis solution for coronary artery calcification; lung texture, a pattern analysis solution for interstitial lung disease, AVIEW LungCAD, a diagnostic aid for automatic detection of lung nodules and masses; and AVIEW AortaLab, a cardiovascular image analysis software.

“AVIEW CHEST is a combination of existing chest and emergency products, enabling an integrated and efficient approach to medical imaging and comprehensive and accurate diagnosis of related diseases,” a Coreline Soft official explained.

With AVIEW CHEST, Coreline Soft aims to establish its leadership position in the thoracic field by quickly and accurately showing imaging changes in the progression of thoracic diseases and treatment effects in screening diseased patients.

"With AVIEW CHEST, we will also expand our entry into the outpatient and inpatient reading market," said Park Joon-min, chief product officer at Coreline Soft. "Computed tomography (CT scan) scans are 20 times more common in the outpatient and inpatient market than screening scans. This is a large market, and we will actively market it."